The following list of StemVacs™ cancer immunotherapy patents are available for licensing.

 

StemVacs-B:
EX VIVO GENERATION OF IMMUNOCYTES RECOGNIZING BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) EXPRESSING CANCER STEM CELLS
StemVacs-E:
CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM
StemVacs-H:
STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF
StemVacs-iPSC Chimera:
COMPOSITIONS CAPABLE OF STIMULATING IMMUNITY TOWARDS TUMOR BLOOD VESSELS
StemVacs-L:
AUGMENTATION OF NATURAL KILLER CELL ACTIVITY AND INDUCTION OF CYTOTOXIC IMMUNITY USING LEUKOCYTE LYSATE ACTIVATED ALLOGENEIC DENDRITIC CELLS: STEMVACS
StemVacs-NK:
STIMULATION OF NATURAL KILL CELL MEMORY BY ADMINISTRATION OF DENDRITIC CELLS
StemVacs-TV:
IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATURE
StemVacs-V:
PLURIPOTENT STEM CELL DERIVED DENDRITIC CELLS AND ENGINEERED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY